GRTS - Gritstone bio Inc. (GRTS) Q1 2024 Earnings Call Transcript
2024-05-09 20:03:10 ET
Gritstone bio Inc. (GRTS)
Q1 2024 Earnings Conference Call
May 09, 2024, 04:30 PM ET
Company Participants
George MacDougall - Director, Investor Relations and Corporate Communications
Andrew Allen - Co-Founder, President, and Chief Executive Officer
Celia Economides - Executive Vice President and Chief Financial Officer
Karin Jooss - EVP and Head of Research and Development
Conference Call Participants
Marc Frahm - TD Cowen
Chengxiang Liu - Evercore
Catherine Novack - JonesTrading
Roy Buchanan - Citizens JMP
Arthur He - H. C. Wainwright
Presentation
Operator
Greetings. My name is Latonya and welcome to Gritstone bio’s, First Quarter 2024 Conference Call. Please note this event is being recorded. At this time I would like to introduce George MacDougall, Head of Investor Relations and Corporate Communications at Gritstone. Please go ahead sir.
George MacDougall
Thank you, Latonya and thank you everyone for joining Gritstone's conference call to discuss our financial results, clinical and business updates for the first quarter of 2024. With me on the call today from Gritstone are Andrew Allen, co-founder President and CEO; Celia Economides, Executive Vice President and Chief Financial Officer and joining us for the Q&A portion will be Karin Jooss, executive vice president and Head of R&D.
Today after the market closed we issued a press release providing corporate updates and financial results for the first quarter of 2024. The press release is available on our website. I’d like to remind you again that today’s call is being webcast live via a link on Gritstone’s Investor Relations website, where a replay will also be available after its completion. After our prepared remarks, we will open up the call for Q&A.
During the course of this call, we will make forward-looking statements that are based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties and actual results may differ materially from those that are described. We encourage you to review the risk factors in our most recent Form 10-Q filed with the U.S. Securities and Exchange Commission and is also available on our website. All statements on this call are made as of today based on information currently available to us. Except as required by law, we disclaim any obligation to update such statements even if our views change. Gritstone hosts these calls on an ad hoc basis and we hope you'll find today's call useful.
With that, let me turn it over to Andrew. Andrew?
Andrew Allen
Thank you, George and good afternoon everybody. And thank you for joining our first quarter 2024 conference call. This is a very exciting time for Gritstone, and I'll begin today's call with a review of our most recent data from our personalized cancer vaccine program GRANITE, as well as provide other clinical and corporate updates. Then Celia will present her financials and I'll come back to share closing remarks....
Gritstone bio Inc. (GRTS) Q1 2024 Earnings Call Transcript